MCID: MYL006
MIFTS: 59

Myeloid Leukemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 11 19 28 53 14 71 75
Myeloid Leukaemia 11 31 33
Myeloid Leukaemia, Unspecified, Without Mention of Remission 33
Myeloid Granulocytic Leukaemia 11
Myeloid Granulocytic Leukemia 11
Non-Lymphocytic Leukemia 11
Granulocytic Leukaemia 33
Leukaemia Myelogenous 11
Myelogenous Leukaemia 33
Leukemia Myelogenous 11
Leukemia, Myeloid 75

Classifications:



External Ids:

Disease Ontology 11 DOID:8692
ICD9CM 34 205
MeSH 43 D007951
NCIt 49 C3172
SNOMED-CT 68 269631008
ICD10 31 C92 C92.9
ICD11 33 2018018546
UMLS 71 C0023470

Summaries for Myeloid Leukemia

GARD: 19 A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.

MalaCards based summary: Myeloid Leukemia, also known as myeloid leukaemia, is related to leukemia, acute myeloid and leukemia, chronic myeloid. An important gene associated with Myeloid Leukemia is MIR99AHG (Mir-99a-Let-7c Cluster Host Gene), and among its related pathways/superpathways are HIF-1-alpha transcription factor network and Wnt/beta-catenin signaling pathway in leukemia. The drugs Nicotine and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include myeloid tissue, myeloid and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance

Disease Ontology: 11 A leukemia that is located in myeloid tissue.

Wikipedia: 75 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(6;9) (p23;q34.1) Acute Myeloid Leukemia with T(8;21); (q22; Q22.1)
Acute Myeloid Leukemia with T(1;22)(p13;q13) Subacute Myeloid Leukemia
Acute Myeloid Leukemia with T(9;11)(p22;q23) Acute Myeloid Leukemia with T(9;22)(q34.1;q11.2)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1754)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 34.0 U2AF1 RUNX1T1 RUNX1 PICALM NUP98 MYH11
2 leukemia, chronic myeloid 33.9 U2AF1 RUNX1 NUP98 MCL1 HOXA9 GATA2
3 core binding factor acute myeloid leukemia 33.5 U2AF1 RUNX1T1 MYH11 FLT3
4 acute myelomonocytic leukemia 33.4 RUNX1 MYH11 FLT3 ETV6 CBFB
5 acute promyelocytic leukemia 33.4 U2AF1 RUNX1T1 RUNX1 NUP98 MYH11 MCL1
6 leukemia 33.3 U2AF1 RUNX1T1 RUNX1 PICALM NUP98 MYH11
7 atypical chronic myeloid leukemia, bcr-abl1 negative 33.3 U2AF1 FLT3 ETV6 ABL1
8 acute erythroid leukemia 33.3 U2AF1 GATA2 FLT3
9 childhood acute myeloid leukemia 33.1 U2AF1 RUNX1T1 NUP98 MYH11 FLT3
10 myelodysplastic syndrome 33.1 U2AF1 RUNX1T1 RUNX1 NUP98 MLF1 HOXA9
11 acute myeloid leukemia with bcr-abl1 32.9 FLT3 ABL1
12 acute myeloid leukemia with t(8;21)(q22;q22) translocation 32.9 RUNX1T1 RUNX1 FLT3
13 chronic myelomonocytic leukemia 32.7 U2AF1 RUNX1 GATA2 FLT3 ETV6 ABL1
14 childhood leukemia 32.7 U2AF1 RUNX1T1 NUP98 MYH11 FLT3 ETV6
15 myeloid sarcoma 32.7 U2AF1 RUNX1T1 FLT3
16 acute basophilic leukemia 32.7 U2AF1 ETV6 ABL1
17 platelet disorder, familial, with associated myeloid malignancy 32.7 RUNX1 ETV6
18 myeloid leukemia associated with down syndrome 32.6 RUNX1T1 MYH11
19 myeloproliferative syndrome, transient 32.6 U2AF1 GATA2 FLT3
20 acute leukemia 32.6 RUNX1T1 RUNX1 NUP98 HOXA9 GATA2 FLT3
21 acute biphenotypic leukemia 32.5 U2AF1 RUNX1T1 FLT3 ETV6 ABL1
22 essential thrombocythemia 32.5 U2AF1 FLT3 ETV6 ABL1
23 leukemia, acute monocytic 32.4 U2AF1 NUP98 FLT3
24 juvenile myelomonocytic leukemia 32.4 U2AF1 RUNX1 NUP98 HOXA9 GATA2 FLT3
25 myeloproliferative neoplasm 32.4 U2AF1 RUNX1 FLT3 ETV6 ABL1
26 hematologic cancer 32.4 U2AF1 RUNX1T1 RUNX1 PICALM NUP98 HOXA9
27 leukemia, acute lymphoblastic 32.3 U2AF1 RUNX1 PICALM MCL1 HOXA9 GATA2
28 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 32.2 ETV6 ABL1
29 acute megakaryocytic leukemia 32.2 U2AF1 RUNX1T1 RUNX1 NUP98 MIR99AHG MIR100HG
30 myelofibrosis 32.0 U2AF1 RUNX1 GATA2 FLT3 ETV6
31 thrombocytopenia 31.9 U2AF1 RUNX1 GATA2 FLT3 ETV6 ABCB1
32 wilms tumor 1 31.9 U2AF1 RUNX1T1 FLT3 ABL1
33 leukemia, chronic lymphocytic 31.8 U2AF1 MCL1 FLT3 ABL1 ABCB1
34 refractory anemia with excess blasts 31.8 U2AF1 GATA2
35 b-lymphoblastic leukemia/lymphoma 31.6 U2AF1 FLT3 ETV6 ABL1
36 lymphoma, non-hodgkin, familial 31.6 U2AF1 MCL1 FLT3 ETV6 ABCB1
37 blood platelet disease 31.5 U2AF1 RUNX1 FLT3 ABL1
38 precursor t-cell acute lymphoblastic leukemia 31.5 PICALM NUP98 FLT3 ETV6 ABL1
39 gastrointestinal stromal tumor 31.5 U2AF1 MYH11 MCL1 FLT3 ETV6 ABL1
40 chronic leukemia 31.5 U2AF1 FLT3 ETV6 ABL1
41 childhood acute lymphocytic leukemia 31.4 RUNX1 MCL1 FLT3 ETV6 ABL1 ABCB1
42 myelodysplastic/myeloproliferative neoplasm 31.2 U2AF1 GATA2 FLT3 ETV6 ABL1
43 central nervous system leukemia 31.1 ETV6 ABL1
44 refractory cytopenia with multilineage dysplasia 31.0 U2AF1 GATA2
45 immunodeficiency 21 31.0 U2AF1 GATA2 FLT3
46 mantle cell lymphoma 31.0 U2AF1 MCL1 FLT3 ABL1
47 rasopathy 31.0 U2AF1 MYH11 GATA2 FLT3 ETV6 ABL1
48 severe congenital neutropenia 31.0 U2AF1 RUNX1 GATA2
49 neutrophilia, hereditary 31.0 U2AF1 FLT3
50 chronic eosinophilic leukemia 30.9 U2AF1 FLT3 ETV6 ABL1

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

25 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 ABCB1 NUP98
2 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.72 ABCB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.72 HOXA9
4 Increased shRNA abundance (Z-score > 2) GR00366-A-141 9.72 ABCB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.72 ABL1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.72 ABL1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.72 NUP98
8 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.72 CBFB HOXA9
9 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.72 ABCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.72 HOXA9
11 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.72 ABL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.72 NUP98
13 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.72 ABL1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.72 ABL1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.72 CBFB
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.72 ABL1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.72 ABL1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.72 CBFB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.72 CBFB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.72 NUP98
21 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 ABL1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.72 ABCB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.72 CBFB
24 Increased shRNA abundance GR00327-A 9.46 ERG FLT3 MCL1 MYH11
25 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.26 GATA2 MCL1 MLF1 RUNX1T1

MGI Mouse Phenotypes related to Myeloid Leukemia:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.32 ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
2 endocrine/exocrine gland MP:0005379 10.23 ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
3 cellular MP:0005384 10.18 ABL1 CBFA2T2 CBFB ERG ETV6 FLT3
4 normal MP:0002873 10.1 ABL1 CBFB ERG ETV6 GATA2 MCL1
5 immune system MP:0005387 10.1 ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
6 embryo MP:0005380 10.09 ABL1 CBFB ERG ETV6 GATA2 MCL1
7 cardiovascular system MP:0005385 10.06 ABCB1 ABL1 CBFB ERG ETV6 GATA2
8 hematopoietic system MP:0005397 10 ABCB1 ABL1 CBFB ERG ETV6 FLT3
9 neoplasm MP:0002006 9.99 CBFB ERG ETV6 FLT3 RUNX1 U2AF1
10 digestive/alimentary MP:0005381 9.95 ABCB1 ABL1 CBFA2T2 CBFB ETV6 MYH11
11 mortality/aging MP:0010768 9.83 ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
12 integument MP:0010771 9.28 CBFB ERG ETV6 HOXA9 MYH11 PICALM

Drugs & Therapeutics for Myeloid Leukemia

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Mitoxantrone Approved, Investigational Phase 4 70476-82-3, 65271-80-9 4212
3
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
4
Daunorubicin Approved Phase 4 20830-81-3 30323
5
Amsacrine Approved, Investigational Phase 4 51264-14-3 2179
6
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
7
Lactitol Approved, Investigational Phase 4 585-86-4 157355
8
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
9
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
10
Lenalidomide Approved Phase 4 191732-72-6 216326
11
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
12
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
13
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731
14
Vitamin D2 Phase 4 3249
15 Calciferol Phase 4
16 Ergocalciferols Phase 4
17 Hydroxycholecalciferols Phase 4
18 HH-GV-678 Phase 4
19 Angiogenesis Inhibitors Phase 4
20
Imatinib Mesylate Phase 4 220127-57-1
21 Tin Fluorides Phase 4
22
Iron Approved Phase 2, Phase 3 7439-89-6 29936
23
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
24
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
25
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
26
Abatacept Approved Phase 3 332348-12-6
27
Lorazepam Approved Phase 3 846-49-1 3958
28
Sargramostim Approved, Investigational Phase 3 123774-72-1
29
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
30
Adenosine Approved, Investigational Phase 3 58-61-7 60961
31
Mercaptopurine Approved Phase 3 50-44-2 667490
32
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
33
Ofloxacin Approved Phase 3 82419-36-1 4583
34
Pentostatin Approved, Investigational Phase 3 53910-25-1 439693
35 Orange Approved Phase 2, Phase 3
36
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4
37
Captopril Approved Phase 3 62571-86-2 44093
38
Morphine Approved, Investigational Phase 3 57-27-2 5288826
39
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
40
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
41
Nalbuphine Approved Phase 3 20594-83-6 5311304
42
Enalaprilat Approved Phase 3 76420-72-9 6917719 5462501
43
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5388962 5362032
44
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 3 55-56-1 2713 9552079
45
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
46
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
47
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
48
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
49
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
50
Coal tar Approved Phase 2, Phase 3 8007-45-2

Interventional clinical trials:

(show top 50) (show all 3307)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
2 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
3 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Unknown status NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
4 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
5 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
6 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
7 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
8 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
9 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
10 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
11 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
12 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
13 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
14 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
15 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
16 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
17 A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA Completed NCT03727750 Phase 4 Gemtuzumab Ozogamicin
18 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
19 Efficacy and Safety of Dasatinib in the First-line Treatment of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Completed NCT04925141 Phase 4 Dasatinib Tablets
20 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
21 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
22 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
23 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
24 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
25 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Completed NCT03176849 Phase 4
26 A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID Completed NCT02546674 Phase 4 Nilotinib
27 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
28 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
29 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV) Completed NCT01578213 Phase 4 Imatinib mesylate
30 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
31 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy Completed NCT01243489 Phase 4
32 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
33 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
34 An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
35 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
36 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
37 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
38 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
39 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
40 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
41 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
42 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Completed NCT02875743 Phase 4 Posaconazole
43 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
44 Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Recruiting NCT04155411 Phase 4 Dasatinib
45 The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in Patients With Chronic Myeloid Leukemia in Chronic Phase: an Randomized Controlled Trial. Recruiting NCT04933526 Phase 4 Flumatinib;Dasatinib
46 A Double-blind , Randomized, Multicenter, Phase 4 Study to Evaluate Efficacy and Safety of Oral Flumatinib 400mg Versus 600mg in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Recruiting NCT05353205 Phase 4 Flumatinib mesylate tablets (400mg);Flumatinib mesylate tablets (600mg)
47 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
48 Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure Recruiting NCT04677439 Phase 4 Flumatinib
49 Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy Recruiting NCT04484532 Phase 4
50 Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte Recruiting NCT04460235 Phase 4 Prevenar13 Pneumo-23

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


dasatinib
imatinib
ponatinib

Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Myeloid Leukemia 28

Anatomical Context for Myeloid Leukemia

Organs/tissues related to Myeloid Leukemia:

FMA: Myeloid Tissue
MalaCards : Myeloid, Bone Marrow, T Cells, Bone, Nk Cells, Spleen, Lymph Node

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 40916)
# Title Authors PMID Year
1
Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature. 53 62
20445327 2010
2
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. 53 62
19880492 2010
3
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 53 62
20084277 2010
4
Transforming growth-interacting factor (TGIF) regulates proliferation and differentiation of human myeloid leukemia cells. 53 62
19699159 2009
5
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. 53 62
19339050 2009
6
[Supportive therapies for myeloid leukemia including blood transfusion and growth factors]. 53 62
19860196 2009
7
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. 53 62
19407318 2009
8
Retraction notice to "The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells" [Blood Cells Mol. Dis. 39 (2007) 307-315]. 53 62
19388154 2009
9
[Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia]. 53 62
19671288 2009
10
[Apoptosis of human myeloid leukemia cell line HL-60 cells induced by siRNA targeting gene c-myc]. 53 62
19379561 2009
11
Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. 53 62
19429444 2009
12
DMNQ-S17 inhibits constitutive NF-kappaB activation leading to induction of apoptosis through the activation of caspase-3 in human myeloid leukemia U937 cells. 53 62
18718843 2008
13
Expression profile of CREB knockdown in myeloid leukemia cells. 53 62
18801183 2008
14
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. 53 62
18059480 2008
15
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion. 53 62
18569848 2008
16
[Dihydroartemisinin down-regulates the expression of transferrin receptor in myeloid leukemia cells]. 53 62
18822958 2008
17
Genomic structure, alternative splicing and expression of TG-interacting factor, in human myeloid leukemia blasts and cell lines. 53 62
18455519 2008
18
Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. 53 62
18483256 2008
19
TGFbeta-mediated formation of pRb-E2F complexes in human myeloid leukemia cells. 53 62
18294958 2008
20
Increased responsiveness to TLR2 and TLR4 ligands during dimethylsulfoxide-induced neutrophil-like differentiation of HL-60 myeloid leukemia cells. 53 62
17664007 2007
21
The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells. 53 62
17644368 2007
22
Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. 53 62
17081606 2007
23
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. 53 62
17644747 2007
24
CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. 53 62
17431504 2007
25
Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. 53 62
17381798 2007
26
Identification of novel nuclear localization signals of Drosophila myeloid leukemia factor. 53 62
18159124 2007
27
Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. 53 62
17213995 2007
28
Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. 53 62
17095538 2007
29
Myeloid leukemia factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U-like molecule. 53 62
17008314 2006
30
Characterization of the Drosophila myeloid leukemia factor. 53 62
17121541 2006
31
Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. 53 62
17043020 2006
32
JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. 53 62
16439016 2006
33
Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. 53 62
17018605 2006
34
[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor]. 53 62
17156654 2006
35
Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. 53 62
16761109 2006
36
HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. 53 62
16457885 2006
37
[Detection of SOCS-1 mRNA expression by RT-PCR in the patients with myeloid leukemia]. 53 62
16928298 2006
38
ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells. 53 62
16473406 2006
39
Cotylenin A-induced differentiation is independent of the transforming growth factor-beta signaling system in human myeloid leukemia HL-60 cells. 53 62
16690533 2006
40
[EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases]. 53 62
16995417 2006
41
[Cytotoxicity of IFN-gamma-activated dendritic cells to freshly isolated acute myeloid leukemia cells]. 53 62
16403283 2005
42
Decitabine activates specific caspases downstream of p73 in myeloid leukemia. 53 62
16193303 2005
43
Effect of clathrin assembly lymphoid myeloid leukemia protein depletion on clathrin coat formation. 53 62
16262731 2005
44
Characterization of 6q abnormalities in childhood acute myeloid leukemia and identification of a novel t(6;11)(q24.1;p15.5) resulting in a NUP98-C6orf80 fusion in a case of acute megakaryoblastic leukemia. 53 62
16028218 2005
45
Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. 53 62
16107889 2005
46
CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. 53 62
15941718 2005
47
[Effect of GPI-PLD on adhesion function of bone marrow mononuclear cell from patients with myeloid leukemia and its mechanism]. 53 62
15972122 2005
48
In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. 53 62
15958635 2005
49
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. 53 62
15609309 2005
50
Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. 53 62
15861129 2005

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 core-binding factor complex GO:0016513 8.92 RUNX1 CBFB

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of DNA-templated transcription GO:0006355 10.11 RUNX1 MLF2 MLF1 HOXA9 GATA2 ETV6
2 DNA-templated transcription GO:0006351 10.03 RUNX1T1 MLF1 HOXA9 CBFA2T2
3 myeloid progenitor cell differentiation GO:0002318 9.71 MLF1 FLT3
4 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.62 CBFB RUNX1
5 positive regulation of extracellular matrix organization GO:1903055 9.56 RUNX1 ABL1
6 hemopoiesis GO:0030097 9.5 RUNX1 PICALM GATA2 FLT3
7 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.46 RUNX1 CBFB
8 definitive hemopoiesis GO:0060216 9.1 HOXA9 GATA2 CBFB

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.1 RUNX1 GATA2 ETV6 ERG CBFB

Sources for Myeloid Leukemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....